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Background
The detection of hepatitis B virus (HBV) in blood donors is achieved by screening for hepatitis B surface antigen (HBsAg) and for antibodies against hepatitis B core antigen (anti-HBc). However, donors who are positive for HBV DNA are currently not identified during the window period before seroconversion. The current use of nucleic acid testing for detection of the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) RNA and HBV DNA in a single triplex assay may provide additional safety.
Methods
We performed nucleic acid testing on 3.7 million blood donations and further evaluated those that were HBV DNA-positive but negative for HBsAg and anti-HBc. We determined the serologic, biochemical, and molecular features of samples that were found to contain only HBV DNA and performed similar analyses of follow-up samples and samples from sexual partners of infected donors. Seronegative HIV and HCV-positive donors were also studied.
T he transfusion of blood containing hepatitis B surface antigen (HBsAg) is associated with post-transfusion infection with hepatitis B virus (HBV). Blood that is free of HBsAg but has high-titer antibodies against hepatitis B core antigen (anti-HBc) in the ab sence of antibodies against hepatitis B surface antigen (anti-HBs) can also transmit HBV infection. 1, 2 In 1986, screening for anti-HBc was implemented in the United States to reduce HBV transmission and as a surrogate marker for non-A, non-B hepatitis (i.e., hepatitis C virus [HCV] ). 3, 4 However, a small proportion of donors with anti-HBc in the absence of HBsAg have circulating HBV DNA and may have a risk of infectivity. [1] [2] [3] [4] [5] [6] Blood that is collected during the early window period of HBV infection is highly infectious, but this risk declines as anti-HBs develops. 5, [7] [8] [9] [10] [11] [12] The estimated residual risk of HBV infection from donations to the American Red Cross ranges from 1 in 280,000 to 1 in 357,000 donations. 13 After the introduction of nucleic acid testing for screening in minipools (pools of 6 to 16 donations), the estimated yield of HBV infection ranges from 1 in 830,000 to 1 in 2 million donations. 14 However, these estimates do not capture the possibility of HBV infection in vaccinated donors who have acute infection with low or no expression of HBsAg. HBV-seronegative but infected donors have been identified by means of nucleic acid testing at a rate of approximately 1 in 600,000 donations screened 15 but have not been further studied. Although the residual risk of transmission of HBV by transfusion has decreased progressively, 13, 16, 17 it remains higher than the estimated risks for human immunodeficiency virus (HIV) and HCV (1 in 1,467,000 donations and 1 in 1,149,000 donations, respectively). 18 We conducted a study to evaluate the use of nucleic acid testing in determining the number of seronegative donors who have HBV DNA and to characterize these donors according to their risk factors and progression of molecular, serologic, and biochemical markers. We used a triplex test combining the detection of HBV DNA with that of HIV and HCV RNA. We also evaluated donors who were seronegative for HIV and HCV but had positive results on nucleic acid testing.
Me thods
Screening Protocol
During 2008, the American Red Cross implemented prospective screening of all blood donations, using the Procleix Ultrio assay and the TIGRIS automated platform 10 (Gen-Probe and Novartis) at three of its five National Testing Laboratories. The American Red Cross collects about 42% of the U.S. blood supply from volunteer, unpaid donors in the continental United States and Puerto Rico. All donations were screened by nucleic acid testing of either individual donations or 16-sample minipools. Blood units that were released for transfusion were negative on triplex nucleic acid testing and for all standard blood-screening markers. 18 All Ultrioreactive minipools were resolved to the reactive individual donation, followed by testing of the reactive individual donations (including donations screened individually by nucleic acid testing) by means of separate discriminatory assays for HBV, HIV, and HCV. Any individual donation with a positive result on nucleic acid testing was not used for transfusion (even if the donor was subsequently determined to have a false positive result), and associated donors were deferred from future donation. Seronegative donors with one or multiple reactive discriminatory tests were considered potentially infected donors for further study. For individual donations, the 95% lower limit of detection for the HBV portion of Ultrio is 10.4 IU per milliliter (approximately 50 copies per milliliter), as compared with approximately 30 copies per milliliter each for HIV and HCV.
The study protocol was approved by the institutional review board of the American Red Cross. Written informed consent for follow-up studies was obtained from donors who were reactive on nucleic acid testing and from their partners. The study was conducted in accordance with the provisions of the protocol.
HBV DNA Confirmation
Donors who were positive for HBV DNA on the Ultrio assay and seronegative for HBsAg (lower limit of detection, 0.10 ng per milliliter) and for total (IgM and IgG) anti-HBc (HBsAg and HBcore PRISM, Abbott Laboratories) were enrolled in follow-up studies, which involved the collection of samples at intervals of 1 to 2 weeks until seroconversion to anti-HBc occurred. Each plasma unit from a reactive donation was retrieved for further testing.
Additional testing that was repeated on all index donations, as well as performed on each follow-up sample, included duplicate Ultrio nucleic acid testing of individual donations and discriminatory testing if reactivity was observed, followed by confirmation by means of polymerase-chain-reaction (PCR) assay with the use of COBAS AmpliScreen HBV Test (Roche) with the 1-milliliter extraction method (95% lower limit of detection, 5 IU per milliliter). In addition, the retrieved plasma units from each donation with reactivity on discriminatory testing were separated into aliquots and tested in replicates of 10 to confirm reactivity. Reactivity in at least 1 of the 10 replicate tests was required for confirmation of positive results; donations with no reactivity were considered to have false positive results.
Serologic testing was performed on retrieved plasma units and follow-up samples for HBsAg, total anti-HBc, qualitative and quantitative antiHBs (Monolisa, Bio-Rad Laboratories), IgM antiHBc (ARCHITECT, Abbott), and alanine aminotransferase (Quest Diagnostics). Donors whose HBV DNA reactivity could be confirmed in index samples or who had serologic evidence of HBV infection in follow-up samples were considered to have HBV infection. The sexual partner of each of these donors was contacted for follow-up, if possible. Screening of a subgroup of donors for anti-HBs was performed as an indicator of HBV vaccine penetrance in the donor population (for details, see the Supplementary Appendix, available with the full text of this article at NEJM .org). Molecular analyses of donor and partner samples were performed in the Geissen and Cambridge laboratories (see the Supplementary Appendix, available with the full text of this article at NEJM.org).
HIV and HCV RNA confirmation
Confirmation of the presence of HIV and HCV RNA included HIV and HCV qualitative and quantitative PCR and HCV genotyping performed at the National Genetics Institute. Antibodies against HIV types 1 and 2 (HIV-1/HIV-2 rDNA EIA, Abbott Laboratories) and HCV (HCV 3.0 ELISA, Ortho Clinical Diagnostics) were used for serologic testing of index and follow-up samples. Serologic confirmation of reactive samples was performed with tests licensed by the Food and Drug Administration. 18 Sexual partners were contacted if possible, as described for HBV confirmation.
Study Oversight
The study was funded in part by Gen-Probe and Novartis Vaccines and Diagnostics, which provided the Ultrio test kits and TIGRIS instruments. The American Red Cross provided a clinical-trial site in support of an investigational protocol designed to determine the frequency of donors who test HBV-seronegative but DNA-positive so that an HBV DNA blood-donation-screening claim could be justified for the Ultrio assay performed on the TIGRIS automated platform. The study protocol was designed and executed by the American Red Cross and its collabor ators. were screened individually by nucleic acid testing and the remainder were screened in minipools. After virus-specific discriminatory testing, 9 HBVseronegative donors were confirmed as having HBV infection by additional testing (1 of 410,540 donations) ( Table 1) . Of the 9 infected donors, 7 (of whom 6 had been vaccinated) consented to participate in the follow-up study, as did the sexual partners of 4 donors. The remaining 2 donors were confirmed as having HBV infection at their index donation from the retrieved plasma unit by repeat nucleic acid testing. All but 1 of the 9 donors with HBV infection were identified by means of minipool nucleic acid testing; the remaining donor (019) required individual-donation nucleic acid testing for detection and tested nonreactive by intermediate dilutions. Of the 9 donors with HBV infection, 8 were repeat donors, and 1 was a first-time donor (055). The mean age of the infected donors was 26 years; 6 of the donors were men.
Detection of HCV and HIV
Fifteen HCV-seronegative donors had confirmed positive results for HCV RNA on PCR assay at their index donation. Repeat nucleic acid testing of the retrieved plasma unit further confirmed the index results, including identical genotypes and similar viral loads. The 15 HCV-infected donors are shown in order of increasing viral load at the index donation (median, 11 million copies per milliliter) in Table 2 . The rate of HCV RNA-positive, seronegative donations was 1 in 246,324 (Table 1) . Of the 15 donors, there was a nearly even split between first-time and repeat donors, with a mean age of 40 years; 10 of the donors were men. The female sexual partner of donor 013-1 was available for testing; the two had the same 3A genotype, implying infection from a common source or through sexual transmission. Two donors had confirmed positive results for HIV RNA on PCR assay at their index donation, with viral loads of 44,000 and 340,000 copies per milliliter ( Table 2) . Testing of the plasma unit confirmed the index test results. These two donors, who were both seronegative, were male repeat donors who were 16 and 29 years of age. The HIV RNA-positive donation rate was 1 in 1,847,429 donations (Table 1) .
In a combined analysis of study findings, among 75 samples from seronegative donors that were reactive on Ultrio and discriminatory testing, there were 26 confirmed infections (9 HBV, 15 HCV, and 2 HIV), or 1 in 153,952 donations. Thus, the positive predictive value for the Ultrio triplex assay in seronegative samples, in- cluding virus-specific discrimination, was 35%, which is similar to the predictive value of other screening assays. Two of the 26 samples required individual-donation nucleic acid testing for detection, for a yield of 1 in 288,470 donations. The rates of detection on serologic analysis were higher than the rates on nucleic acid testing for all three viruses, underscoring the need for both nucleic acid testing and serologic screening ( Table 1) .
Course of HBV Infection in Index Donors
The HBV viral load was consistently low in all index samples from the nine infected donors (11 to 86 IU per milliliter) ( four of the five were positive for anti-HBs and for HBV DNA at baseline. Transiently low levels of HBsAg were observed in two of these donors (011 and 042), whereas anti-HBs remained reactive (Table 3 and Fig. 1B ). In these two donors, an increase in anti-HBs corresponded to the disappearance of HBsAg. IgM and total anti-HBc became positive on day 107 in one donor (042) and on day 168 in the other (011). Donor 013 did not have detectable HBsAg or anti-HBc for 9 months, but an increase in anti-HBs occurred on day 42, when HBV DNA became undetectable (Table 3 and Fig. 1B) . The fourth donor (003) had received a plasma-derived HBV vaccine 27 years earlier; her level of anti-HBs in the index donation (3 IU per liter) was considered to be nonimmune. HBV DNA remained detectable for up to 70 days, at which time IgM and total anti-HBc appeared. HBsAg was never detected; however, an anamnestic response for anti-HBs was observed in the first follow-up sample (obtained on day 20). A fifth vaccinated donor (001) was negative for anti-HBs at baseline but had seroconversion (100 IU per liter) within 45 days, a finding that was consistent with an anamnestic response, since it preceded the detection of total and IgM anti-HBc by up to 24 days. Despite the detection of IgM antiHBc in four of the five vaccinated donors, no increased levels of alanine aminotransferase were noted, which further substantiated the inconsequential nature of these infections. HBV genotypes or subgenotypes of the 6 vaccinated donors were C2 (in donor 001), A2 (in donor 003), F1 (in donor 011), B2 (in donor 013), and sequences representing both D and A2 (in donors 029 and 042), as compared with A2 in all unvaccinated donors (P = 0.048 by Fisher's exact test, two-tailed, for the comparison between the dominant strains in the 6 vaccinated donors and in the 3 unvaccinated donors) ( Table 3 and Fig. 2 , and the Supplementary Appendix). Figure 3 shows the levels of anti-HBs in 520 randomly selected donors who were not infected with HBV. Of the 231 immune donors in this subgroup (44%), more than 65% were 29 years of age or younger, which was consistent with the mean age of 26 years for the 9 donors with HBV infection, of whom 6 had also been vaccinated.
Origin of HBV Infection
The sexual partners of infected donors were traced when possible, and four were found to have HBV infection. In all cases, the sequences of the presurface and surface (pre-S/S) regions of the HBsAg gene were nearly identical at the nucleotide level (<0.1% divergence) and the amino acid level in two laboratories, as were the full genome sequences in donor 013 and his sexual partner, which strongly suggests that infection occurred between vaccinated donors and their sexual partners who carried high viral loads (>1.0×10 6 IU per milliliter) ( Table 3 ). All these partners were highly positive for HBsAg and anti-HBc but were negative for anti-HBs and IgM anti-HBc, indicating chronic carriage. Three of the four partners had mild alanine aminotransferase elevations (range, 31 to 38 U per liter), which were consistent with chronic hepatitis B. The transfer of a mutated minority variant to one donor (001) from his partner further confirms sexual transmission and immune selection. The fifth and sixth vaccinated donors were health care workers whose acute infections were probably the result of occupational exposure.
Discussion
Analysis of the results of blood-donor testing, along with follow-up analyses of infected donors, permits assessment of the details of early infection and modeling of the residual risk of infectivity from transfusion. 13, 18 In this study, we found some unexpected patterns of early HBV infection as a result of evaluating HBV nucleic acid testing among 3.7 million blood donations. On the basis of modeling studies, we anticipated two to four seronegative, HBV DNA-positive samples from minipool nucleic acid testing and one seronegative, HBV DNA-positive sample from single-donation testing. 14 In fact, we found nine seronegative, HBV DNA-positive samples, and all but one were detected on minipool nucleic acid testing, for a total rate of 1 per 410,540 donations. Three of the infected donors appeared to have conventional window-period infection, which was consistent with expected findings. Unexpectedly, five of the other six infected donors had low- 244 liter at donation. Four of the five vaccinated donors who were followed were also positive for IgM anti-HBc, confirming acute infection. Smaller studies in the United States have typically shown approximately one HBV-infected donor per 600,000 donations screened. 15 In countries where HBV infection is endemic, rates are much higher. 10, 19 The three acute infections among nonvaccinated donors were of subgenotype A2, which is the most frequent genotype in the United States and is the parent strain of the HBV vaccine. Elevations in alanine aminotransferase levels developed in two of these donors (119 and 640 U per liter) during follow-up. In contrast, only one of the six previously vaccinated donors was uniquely infected with the A2 strain; she had received the plasma-derived vaccine 27 years earlier. All other donors were infected exclusively or predominantly with non-A2 strains. None of the vaccinated donors had any signs of elevated levels of alanine aminotransferase. Overall, the data emphasize the protective effect of the vaccine, since the observed infections were transient, blunted, and without effect on liver function. Our findings thus suggest that the vaccine may be less effective for non-A2 infections. Of interest, four donors with acute HBV infection were discovered to have sexual partners who were chronic HBV carriers with high viral loads of wild-type (or in one case, mutated) HBV DNA. These infected donors had the same subgenotype and full genome sequences compatible with transmission.
The blood of donors with acute HBV DNApositive infection during the window period is likely to be highly infectious in transfusion recipients. 11, 12 The significance of infection in vaccinated donors is less clear. In one study, blood donations that were positive for HBV DNA with detectable levels of anti-HBs were not infectious in any of 22 recipients, as compared with a rate of infection of 27% among 37 recipients of blood that was devoid of anti-HBs. 11 Similarly, the absence of infectivity in the presence of antiHBs has been observed in other studies. 2, [20] [21] [22] [23] Conversely, blood containing HBV DNA with low-level anti-HBs (<75 IU per liter) may carry a risk of transmission leading to acute hepatitis. 24 These study findings may be relevant to decisions about the need to implement screening for HBV DNA among blood donors.
The rates of RNA-positive HIV and HCV infection among seronegative donations in our study (1 in 1.85 million for HIV and 1 in 246,000 for HCV) parallel those observed by the American Red Cross among more than 66 million donations tested in the 10 years since the introduction of nucleic acid testing for HIV and HCV (32 HIV-positive donations, or 1 in 2 million, and 244 HCV-positive donations, or 1 in 270,000) 18 and are consistent with earlier reports. 25 The characteristics of the 15 donors with HCV infection and the 2 donors with HIV infection in our study were similar to those reported previously. 18 The infrequent detection of transfusiontransmitted infection contributes to the low cost-effectiveness of nucleic acid testing (for details, see the Supplementary Appendix). 26, 27 During 10 years of nucleic acid testing for HIV and HCV in the United States, five HIV-infected donors have transmitted the virus to six of eight living transfusion recipients. Two recipients were infected by one donor, and two other windowperiod donors each infected one recipient. In two cases, only one of two living recipients became infected; of these last two cases of differential transmission (i.e., in which one recipient became infected and the other did not), one case is unpublished. [28] [29] [30] [31] In contrast, there has been Individual strains that are included in the study are shown in red, and genotype references from GenBank are shown in black. Study samples are coded as ARC (indicating the American Red Cross), followed by a three-digit code number. The abbreviation "ind" indicates an index sample, and "part" indicates a sample from a sexual partner of an index donor. Sample codes ending with "cam" indicate consensus sequences obtained in the Cambridge laboratory. Sample codes preceded by "cons" indicate consensus of all clones obtained at the Giessen laboratory for a particular strain. For the two samples that were identified as being coinfected with two different genotypes, "cl" plus a number indicates the clone number within a sample quasispecies. In all cases, consensus sequences that were obtained either in Cambridge or in Giessen were identical or differed by fewer than three nucleotides. only one report of suspected transmission of HCV through transfusion. 32 For HBV, there has been no documentation of transmission through transfusion in the United States since the introduction of ultrasensitive screening for HBsAg in 2006. The two cases of differential transmission of HIV that were observed by the American Red Cross, in which a high-volume plasma component transmitted the virus but packed red cells containing low amounts of plasma did not, indicate that the sensitivity of nucleic acid testing, even in minipools, may approach the threshold for infection. In any event, since the implementation of nucleic acid testing and sensitive serologic assays, viral transmission by transfusion from donors who previously had negative results on both serologic and nucleic acid testing is a rare finding 27 (for details, see the Supplementary Appendix). In summary, this study showed a higherthan-expected rate of HBV infection with the use of triplex nucleic acid testing, mainly in donors who had been vaccinated against HBV and who would not have been identified by routine screening for HBsAg or anti-HBc. However, these acute HBV infections rapidly resolved and are of inconsequential clinical significance, but their potential for transmission remains unresolved. Our findings show the efficacy of the HBV vaccine for the prevention of clinical disease but not infection, and the cost of interdicting donations that contain HBV DNA from seronegative donors is high in the face of unknown benefit. Because of the high cost of introducing new screening assays for blood donors and the inability to document cost-effectiveness similar to that of other medical interventions, the continued development of new tests either to replace older tests or to detect newly identified agents 33 is in question. 
